MAPS PBC

AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect

Could MDMA Revolutionize PTSD Treatment? In Historic Move, FDA Considers New Drug Application

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More

Could MDMA Revolutionize PTSD Treatment? In Historic Move, FDA Considers New Drug Application

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

MDMA Therapy For PTSD Nearing Legalization In US And Worldwide, MAPS Releases Promising Data

MAPS PBC Recent News

MDMA Therapy For Chronic PTSD: Neuroimaging With Veterans & First Responders Provides Further Evidence

The legendary non-profit’s private arm, MAPS Public Benefit Corporation (MAPS PBC), announced that Frontiers in Psychiatry has published its first functional neuroimaging study evaluating how MDMA-assisted therapy work

Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More

Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's Senate Health Committee.

MDMA For PTSD Shows Positive Results In Important Clinical Trial: Are Psychedelic Treatments Around The Corner?

MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therap

MAPS Completes Second Phase 3 Trial Of MDMA-Assisted Therapy For PTSD, Topline Data & New Drug Application Next

MAPS Public Benefit Corporation (PBC) announced the final participant’s last Evaluation and Exit Planning therapeutic session was completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD.)

Can Psychedelics Therapy Training Become A Profitable Business? We Asked Industry Insiders

Demand for specialized therapists capable of providing psychedelics-assisted treatments is expected to continue growing. At the same time, the number of people willing to get trained is expanding.